Bridging vs Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness Analyses
<p dir="ltr">The warfarin peri-procedural management in Qatar is predominantly based on bridging (63%), compared to non-bridging. This study sought to perform a first-time cost analysis of current warfarin peri-procedural management practices, including a cost-effectiveness analysis...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , |
| Published: |
2021
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513545417261056 |
|---|---|
| author | Islam Eljilany (14151588) |
| author2 | Hazem Elewa (3592601) Osama Abdelsamad (14151600) Mohamed Abdelgelil (16515261) Ahmed Mahfouz (737928) Rasha Al Anany (17302822) Sumaya Al Yafei (17302825) Daoud Al-Badriyeh (832403) |
| author2_role | author author author author author author author |
| author_facet | Islam Eljilany (14151588) Hazem Elewa (3592601) Osama Abdelsamad (14151600) Mohamed Abdelgelil (16515261) Ahmed Mahfouz (737928) Rasha Al Anany (17302822) Sumaya Al Yafei (17302825) Daoud Al-Badriyeh (832403) |
| author_role | author |
| dc.creator.none.fl_str_mv | Islam Eljilany (14151588) Hazem Elewa (3592601) Osama Abdelsamad (14151600) Mohamed Abdelgelil (16515261) Ahmed Mahfouz (737928) Rasha Al Anany (17302822) Sumaya Al Yafei (17302825) Daoud Al-Badriyeh (832403) |
| dc.date.none.fl_str_mv | 2021-11-01T09:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.cpcardiol.2021.100839 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Bridging_vs_Non-Bridging_with_Warfarin_Peri-Procedural_Management_Cost_and_Cost-Effectiveness_Analyses/24459124 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences Economics Econometrics Bridging Non-Bridging Cost-Effectiveness Analyses Warfarin Peri-Procedural Management |
| dc.title.none.fl_str_mv | Bridging vs Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness Analyses |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">The warfarin peri-procedural management in Qatar is predominantly based on bridging (63%), compared to non-bridging. This study sought to perform a first-time cost analysis of current warfarin peri-procedural management practices, including a cost-effectiveness analysis (CEA) of predominant bridging vs predominant non-bridging practices. From the hospital perspective, a one-year decision-analytic model followed the cost and success consequences of the peri-procedural warfarin in a hypothetical cohort of 10,000 atrial fibrillation patients. Success was defined as survival with no adverse events. Outcome measures were the cost and success consequences of the 63% bridging (vs not-bridging) practice in the study setting, ie, Hamad Medical Corporation, Qatar, and the incremental cost-effectiveness ratio (ICER, cost/success) of the warfarin therapy when predominantly bridging based vs when predominantly non-bridging based. The model was based on Monte Carlo simulation, and sensitivity analyses were performed to confirm the robustness of the study conclusions. As per 63% bridging practices, the mean overall cost of peri-procedural warfarin management per patient was USD 3,260 (QAR 11,900), associated with an overall success rate of 0.752. Based on the CEA, predominant bridging was dominant (lower cost, higher effect) over the predominant non-bridging practice in 62.2% of simulated cases, with a cost-saving of up to USD 2,001 (QAR 7,303) at an average of USD 272 (QAR 993) and was cost-effective in 36.9% of cases. Being between cost-saving and cost-effective, compared to predominant non-bridging practices, the predominant use of bridging with warfarin seems to be a favorable strategy in atrial fibrillation patients.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2021.100839" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2021.100839</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_42c089999fc90dead0574842f049c1b9 |
| identifier_str_mv | 10.1016/j.cpcardiol.2021.100839 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/24459124 |
| publishDate | 2021 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Bridging vs Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness AnalysesIslam Eljilany (14151588)Hazem Elewa (3592601)Osama Abdelsamad (14151600)Mohamed Abdelgelil (16515261)Ahmed Mahfouz (737928)Rasha Al Anany (17302822)Sumaya Al Yafei (17302825)Daoud Al-Badriyeh (832403)Biomedical and clinical sciencesCardiovascular medicine and haematologyClinical sciencesPharmacology and pharmaceutical sciencesEconomicsEconometricsBridgingNon-BridgingCost-Effectiveness AnalysesWarfarin Peri-Procedural Management<p dir="ltr">The warfarin peri-procedural management in Qatar is predominantly based on bridging (63%), compared to non-bridging. This study sought to perform a first-time cost analysis of current warfarin peri-procedural management practices, including a cost-effectiveness analysis (CEA) of predominant bridging vs predominant non-bridging practices. From the hospital perspective, a one-year decision-analytic model followed the cost and success consequences of the peri-procedural warfarin in a hypothetical cohort of 10,000 atrial fibrillation patients. Success was defined as survival with no adverse events. Outcome measures were the cost and success consequences of the 63% bridging (vs not-bridging) practice in the study setting, ie, Hamad Medical Corporation, Qatar, and the incremental cost-effectiveness ratio (ICER, cost/success) of the warfarin therapy when predominantly bridging based vs when predominantly non-bridging based. The model was based on Monte Carlo simulation, and sensitivity analyses were performed to confirm the robustness of the study conclusions. As per 63% bridging practices, the mean overall cost of peri-procedural warfarin management per patient was USD 3,260 (QAR 11,900), associated with an overall success rate of 0.752. Based on the CEA, predominant bridging was dominant (lower cost, higher effect) over the predominant non-bridging practice in 62.2% of simulated cases, with a cost-saving of up to USD 2,001 (QAR 7,303) at an average of USD 272 (QAR 993) and was cost-effective in 36.9% of cases. Being between cost-saving and cost-effective, compared to predominant non-bridging practices, the predominant use of bridging with warfarin seems to be a favorable strategy in atrial fibrillation patients.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2021.100839" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2021.100839</a></p>2021-11-01T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.cpcardiol.2021.100839https://figshare.com/articles/journal_contribution/Bridging_vs_Non-Bridging_with_Warfarin_Peri-Procedural_Management_Cost_and_Cost-Effectiveness_Analyses/24459124CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/244591242021-11-01T09:00:00Z |
| spellingShingle | Bridging vs Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness Analyses Islam Eljilany (14151588) Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences Economics Econometrics Bridging Non-Bridging Cost-Effectiveness Analyses Warfarin Peri-Procedural Management |
| status_str | publishedVersion |
| title | Bridging vs Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness Analyses |
| title_full | Bridging vs Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness Analyses |
| title_fullStr | Bridging vs Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness Analyses |
| title_full_unstemmed | Bridging vs Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness Analyses |
| title_short | Bridging vs Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness Analyses |
| title_sort | Bridging vs Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness Analyses |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences Economics Econometrics Bridging Non-Bridging Cost-Effectiveness Analyses Warfarin Peri-Procedural Management |